ANTX
vs
S&P 500
ANTX
S&P 500
Over the past 12 months, ANTX has underperformed S&P 500, delivering a return of -20% compared to the S&P 500's +14% growth.
Stocks Performance
ANTX vs S&P 500
Performance Gap
ANTX vs S&P 500
Performance By Year
ANTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
AN2 Therapeutics Inc
Glance View
AN2 Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Menlo Park, California and currently employs 22 full-time employees. The company went IPO on 2022-03-25. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The firm is focused on advancing its first product candidate, epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease. Epetraborole is a boron-containing, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA, or tRNA, molecules in protein synthesis. The company is focused on developing epetraborole to treat Mycobacterium avium complex (MAC). The Company’s core technology approach is based on the use of boron chemistry for its research and development initiatives. Boron has a distinctive ability to bind with biological targets through a reversible covalent bond and the potential to address biological targets that have been difficult to inhibit using traditional carbon-based molecules.
